ORPHA:99757
Embryonal rhabdomyosarcoma
Publications
4,483
Trials
8
Interventional, condition-specific
Researchers
1,205
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009993
- OMIM:268210
- UMLS:C0206656
- NCIT:C8971
Additional Mondo synonyms (5)
ERMS · embryonal rhabdomyosarcoma · embryonal rhabdomyosarcoma (disease) · rhabdomyosarcoma, embryonal, type 1 · rhabdomyosarcoma, somatic
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
4,483 matched papers (2,215 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
8 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
4,483
4,483 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
4,483 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
2,215 in the last 10 years · low confidence
Phrase hits: 4,483 · MeSH hits: 0
Who's working on it?
1,205
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Antonescu CR4 papers · 2026
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Papers in Europe PMC - 02Dermawan JK4 papers · 2026
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Papers in Europe PMC - 03Li S4 papers · 2026
Department of Urology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Papers in Europe PMC - 04Zhang Y4 papers · 2026
Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Papers in Europe PMC - 05Jia Y3 papers · 2026
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Papers in Europe PMC - 06Li Y3 papers · 2026
Department of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200040, China.
Papers in Europe PMC - 07Sun L3 papers · 2026
Key Laboratory of Birth defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China.
Papers in Europe PMC - 08von Deimling A3 papers · 2026
Department and CCU Neuropathology, University Hospital Heidelberg and German Cancer Center (DKFZ), Heidelberg, Germany.
Papers in Europe PMC - 09Zhou D3 papers · 2026
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Papers in Europe PMC - 10Zhou Y3 papers · 2026
College of Life Sciences, Yan'an University, Yan'an, 716000, People's Republic of China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
8
interventional trials for this specific condition
8 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 204 trials are registered for rhabdomyosarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
8 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 90.6th percentile).
low confidence · 90.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
8 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06669013·RECRUITING·Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
Conditions: Bone Sarcoma · Embryonal Rhabdomyosarcoma · Alveolar Rhabdomyosarcoma·Matched via name phrase
- NCT05304585·RECRUITING·Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Conditions: Embryonal Rhabdomyosarcoma · Fusion-Negative Alveolar Rhabdomyosarcoma · Spindle Cell/Sclerosing Rhabdomyosarcoma·Matched via name phrase
Broader category: rhabdomyosarcoma
204
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT03054792·ENROLLING BY INVITATION·Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas
Conditions: Rhabdomyosarcoma · Non-Rhabdo. Soft Tissue Sarcoma·Matched via name phrase
- NCT06625190·RECRUITING·Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Conditions: Neuroblastoma · Rhabdomyosarcoma · Synovial Sarcoma · Peripheral Nerve Sheath Tumors·Matched via name phrase
- NCT07444918·NOT YET RECRUITING·Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Conditions: Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)·Matched via name phrase
- NCT07224568·NOT YET RECRUITING·Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
Conditions: Solid Tumor (Excluding CNS) · Hepatocellular Carcinoma · Liver Cell Carcinoma · Liposarcoma·Matched via name phrase
- NCT07516353·NOT YET RECRUITING·my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Conditions: Sarcoma · Osteosarcoma · Ewing Sarcoma · Rhabdomyosarcoma·Matched via name phrase
- NCT06836492·RECRUITING·A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Conditions: Rhabdomyosarcoma · Pediatric Cancer·Matched via name phrase
- NCT04308330·RECRUITING·Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Conditions: Ewing Sarcoma · Rhabdomyosarcoma · Wilms Tumor · Neuroblastoma·Matched via name phrase
- NCT07584499·RECRUITING·Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) · Nasopharyngeal Carcinoma · Lymphoepithelial Carcinoma · Rhabdomyosarcoma·Matched via name phrase
- NCT07169344·RECRUITING·Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
Conditions: Soft Tissue Sarcoma (Excluding GIST) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name phrase
- NCT02508038·RECRUITING·Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Conditions: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Hodgkin Lymphoma · Non-Hodgkin Lymphoma·Matched via name phrase
- NCT06683846·RECRUITING·Ivonescimab in the Treatment of Multiple Advanced Tumors
Conditions: Pheochromocytoma/Paraganglioma · Rhabdomyosarcoma · Paget Disease, Extramammary · Renal Angiomyolipoma·Matched via name phrase
- NCT06796543·RECRUITING·Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Conditions: Metastatic Sarcoma · Radiation Therapy Patient · Ewing Sarcoma · Rhabdomyosarcoma·Matched via name phrase
- NCT06721689·RECRUITING·PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Conditions: Refractory Solid Tumors · Relapsed Solid Tumors · Relapsed Neuroblastoma · Refractory Neuroblastoma·Matched via name phrase
- NCT07173972·RECRUITING·Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Conditions: Soft Tissue Sarcoma (STS) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name phrase
- NCT06239272·RECRUITING·NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Conditions: Adipocytic Neoplasm · Liposarcoma · Atypical Fibroxanthoma · Angiomatoid Fibrous Histiocytoma·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03382158·RECRUITING·International PPB/DICER1 Registry
Conditions: Pleuropulmonary Blastoma · Sertoli-Leydig Cell Tumor · DICER1 Syndrome · Cystic Nephroma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Embryonal rhabdomyosarcoma" OR "embryonal rhabdomyosarcoma (disease)" OR "rhabdomyosarcoma, embryonal, type 1" OR "rhabdomyosarcoma, somatic"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Embryonal rhabdomyosarcoma" OR "embryonal rhabdomyosarcoma (disease)" OR "rhabdomyosarcoma, embryonal, type 1" OR "rhabdomyosarcoma, somatic"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 8 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"rhabdomyosarcoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ERMS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (4483) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T06:16:16.532Z
